Patent ID: 11857619
Assignee: JANSSEN VACCINES & PREVENTION B.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A process for purifying HIV-1 gp140 protein, comprising the steps of:
i) providing a composition comprising HIV-1 gp140 protein and other, non-desired host cell proteins derived from the host cell in which HIV-1 gp140 protein is expressed;
ii) capturing the HIV-1 gp140 protein on a multimodal resin comprising hydrophobic interaction and cation exchange properties, and eluting a purified fraction comprising the HIV-1 gp140 protein from the multimodal resin, wherein the multimodal resin comprising hydrophobic interaction and cation exchange properties comprises a solid support matrix with the following attached ligand of, iii) applying the purified fraction of step ii) to an anion exchange resin to bind the HIV-1 gp140 protein, and eluting a further purified fraction comprising the HIV-1 gp140 protein from the anion exchange resin, wherein the anion exchange resin comprises a solid support matrix with a ligand of quaternary polyethyleneimine;
iv) applying the further purified fraction of HIV-1 gp140 protein of step iii) to an affinity medium resin comprising the ligand dextran sulfate, and eluting a further purified fraction comprising the HIV-1 gp140 protein from said resin; and,
v) subjecting the further purified fraction of step iii) to a multimodal resin that has anion-exchange and hydrophobic functionalities, wherein the multimodal resin that has anion-exchange and hydrophobic functionalities comprises a solid support matrix with a ligand of, , and eluting a further purified HIV-1 gp140 protein.